Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.
Researchers observed this correlation independent of patients’ response to treatment per RECIST criteria.
“Patients with metastatic uveal melanoma treated with tebentafusp may have clinical benefit even though they do not get tumor shrinkage — or even see growth — on scans,” Alexander N. Shoushtari, MD, medical oncologist at Memorial Sloan